They do not rebuild the system required for metabolic resilience, a system that sits at the center of GLP-1 microbiome science and is powered primarily by the gut microbiome, SCFAs, inflammation control, circadian timing, and mucosal structure
Just like the other versions of this drug, it does cause some gastrointestinal issues, which are nausea, vomiting, cramping, constipation, and diarrhea
However, if HbA1c level is more than 1% from the target, metformin combined with insulin and then/or a glucagon-like peptide 1 receptor agonist (GLP-1 RA) is recommended with or without sulfonylurea [4]
It is being studied for the treatment of T2DM, Obesity, Osteoarthritis , and Obstructive Sleep Apnea with a planned simultaneous submission strategy
The FDA approved once-daily oral semaglutide (Wegovy) at 25 mg on 22 December 2025, making it the first oral GLP-1 approved specifically for chronic weight management in the US